Translating mRNA
Educational Webinar Series
The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series titled Translating mRNA, which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information, including recent study results to support healthcare providers’ knowledge regarding Pfizer and BioNTech’s COVID-19 vaccines including the COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5).
The webinar series will include a live question-and-answer session with Pfizer medical experts.
We are hosting Translating mRNA sessions on the topic below. You are welcome to attend multiple sessions, but please register for each date separately. Please see below for dates and times.
Select COVID-19 Vaccine Updates from February ACIP Meeting
Date and Time:
1. Wednesday, 22 March 2023: 12:00 PM – 1:00 PM EST or
2. Thursday, 23 March 2023: 4:00 PM – 5:00 PM EST
Speaker: Rajeev M Nepal, PhD
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA
Target Audience: All healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
Emergency uses of the vaccines have not been approved or licensed by the US Food and Drug Administration (FDA) but have been authorized by the FDA under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For more information, please see the full Prescribing Information and EUA Fact Sheets for Vaccination Providers available at cvdvaccine-us.com.
